drugset / Trial / NCT03426254
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess the safety and efficacy of two forms of Talazoparib therapy (injections subcutaneously Talazoparib and oral form for the treatment in the equivalent therapeutics dose
Timeline
- Start
- 2022-11-10
- Primary completion
- 2023-12-10
- Completion
- 2024-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talazoparib | Small molecule | 1 mg | Subcutaneous |